News Focus
News Focus
Followers 36
Posts 3431
Boards Moderated 1
Alias Born 10/24/2015

Re: axelvento post# 13925

Friday, 05/23/2025 9:00:40 PM

Friday, May 23, 2025 9:00:40 PM

Post# of 14183
They are developing a next generation anti-PD-L1 t-haNK cell line equipped with inducible safety switch features to remove the need for irradiation. Also, modifications that could limit rejection after infusion, as well as cytokine-induced memory-like expansion.

Personally, I think they should have switched some years ago to developing iPSC-derived CAR (and/or TCR) cell therapies. One benefit of using iPSCs is that the cell lines can be differentiated into any cell type of the body.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News